TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

KILL Teva Announces Launch of Generic Epzicom® Tablets in the United States

Teva Pharmaceutical Industries Ltd. requests that their press release NewsItemId: 20160928005512 entitled “Teva Announces Launch of Generic Epzicom® Tablets in the United States” be killed.

The release was issued by Teva Pharmaceutical Industries Ltd. without final FDA approval.

A replacement release will be issued at a later time.

EN
28/09/2016

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

Si Yong Ng
  • Si Yong Ng
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
09/10/25 September 10, 2025 1 EN
Felix Fischer ... (+6)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
TEVA.N Teva Pharmaceut...
DBG DERICHEBOURG SA ... (+6)

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Mahle, Guala Closures, Playtech, Grupo Antolin, NewDay, Kiloutou, David Lloyd Leisure, Omnia Technologies, Cirsa, evoke, Derichebourg, Seche Environnement, Samvardhana Motherson, Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
DBG DERICHEBOURG SA
888 888 HOLDINGS PLC
PL8 PLAYTECH PLC
SECVY SECHE ENVIRONNEMENT
CIRSA CIRSA
09/10/25 September 10, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatmen...

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally invol...

September 9, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva to Present at Morgan Stanley Global Healthcare Conference and Ban...

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceTuesday, September 9, 2025, at 8:30 A.M. ET BofA Global Healthcare Conference 2025 (London)Wednesday, September 24, 2025, at 9:00 A.M. ...

September 2, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutid...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and pediatric patients (12-17 year...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch